SMMT is trading 4% up now at $14.96 after a stretch of volatile biotech trading and earlier news around its ivonescimab program. Recent weeks saw sharp moves linked to trial data disappointment and mixed sentiment, but there is no fresh, clearly identified catalyst or headline on July 2, 2026 specifically driving today’s modest rebound, which may partly reflect broader market strength.